FILING ANALYSIS · FRIDAY, NOVEMBER 6
TREACE MEDICAL CONCEPTS, INC. TMCI — 8-K: Results of Operations and Financial Condition
neutral
TMCI reported a narrower net loss and improved Adjusted EBITDA, with revenue of $48.3 million in the third quarter, and updated its full-year 2026 revenue guidance to $206-210 million, representing a decline of 3% to 1% compared to full-year 2025. The company also reduced its expected Adjusted EBITDA loss for the full year.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →